

بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكرو فيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





بعض الوثائق الأصلية تالفة





بالرسالة صفحات لم ترد بالأصل



RECENT ADVANCES IN ARTIFICIAL BLOOD SUBSTITUTES AND OXYGEN CARRIERS

Essay

Submitted for Complete Fulfillment of
The Master Degree (M.Sc.) degree in
Anesthesia and ICU

By

Dina Abd Eltwab Mohammed Turki
(M.B.; B.Ch., Cairo University)

Under supervision of

Prof. Dr. Wafaa Mohammed Alsadek
*Professor of Anesthesia,
Faculty of Medicine, Cairo University*

Dr. Nashwa Samy Alzayat
*Assistant Professor of Anesthesia
Faculty of Medicine, Cairo University*

Dr. Amira Refaie Hassan
*Lecturer of Anesthesia,
Faculty of Medicine, Cairo University*

**Faculty of Medicine,
Cairo University
2011**

ACKNOWLEDGEMENT

*It is a great honour to express my deep gratitude and appreciation to Professor Dr. **Wafaa Mohammed Alsadek**, Professor of Anesthesia Faculty of Medicine, Cairo University, for her encouragement, fatherhood and his guidance throughout the study.*

*I would like to express my sincere thanks and deep gratitude to Dr. **Nashwa Samy Alzayat**, Assistant Professor of Anesthesia, Faculty of Medicine, Cairo University, for her energetic follow up with constructive advice, criticism and creative suggestions.*

*I am also grateful to Dr. **Amira Refaie Hassan**, Lecturer of Anesthesia, Faculty of Medicine, Cairo University, for her valuable advice and encouragement throughout the entire study.*

Last, but not least, I would like to thank all members of the Department of Anesthesia, Faculty of Medicine, Cairo University for their help.

ABSTRACT

Blood substitutes are oxygen-carrying, volume expanding solutions. they include; perfluorocarbons and hemoglobin- based solutions. They are used as alternatives to natural human blood transfusion to decrease the incidence of complications that may result from homologous blood transfusion and to face the probable coming shortness of blood donation.

Keywords:

Oxygen; Carrying; Volume expanding; Perfluorocarbons;
Hemoglobin-based; Complications; Donation

CONTENTS

	Page
▪ Introduction	1
▪ Aim of the Work	4
▪ Chapter 1: Physiology of blood	6
▪ Chapter 2: Physiology of oxygen transport	18
▪ Chapter 3: Complications of blood transfusion	24
▪ Chapter 4: Artificial Blood Substitutes	37
▪ Summary	81
▪ References	84
▪ Arabic Summary	100

LIST OF FIGURES

No.	Title	Page
1	Showing schematic visual model of oxygen binding process	13
2	Showing oxy hemoglobin	14
3	Oxygen-haemoglobin dissociation curve	21
4	Chemical structures of two PFCs: perfluorodecalin (top) and perflubron (bottom)	44
5	The oxygen content of perfluorocarbon emulsions obeys Henry's Law of partial pressures; the amount of oxygen dissolved in a perfluorocarbon solution is directly related to the partial pressure of oxygen to which the solution is exposed	45
6	Schematic relationship between oxygen content and oxygen partial pressure (pO ₂) for haemoglobin (Hb) and a perfluorochemical (PFC) liquid. Note the linear relationship between these variables for the PFC	45
7	Showing Hemoglobin-based blood substitutes	56
8	A comparison of the oxy- hemoglobin dissociation curves of native ("wild-type" or A1) hemoglobin contained with the normal red blood cell milieu ("RBC-Enclosed Native Hemoglobin"), native or "wild-type" hemoglobin after removal from a red blood cell ("Stroma Free Native Hemoglobin"), and typical hemoglobin based oxygen carrier solutions	58
9	Erythrocytes (RBC), micron-dimension and nano-dimension artificial RBC containing haemoglobin and enzymes. This nanodimension combined with the use of a composite biodegradable polymeric membrane (polylactide-polyethylene glycol) have resulted in a circulation time that is double that of PolyHb (49). Updated and reprinted with permission from: Chang, TMS. Blood Substitutes. Karger Publisher, Basel, 1997, courtesy of copyright holder	75
10	Nano-dimension artificial red blood cells containing haemoglobin and RBC enzymes. Updated and Reprinted with permission from: Chang. TMS. Artificial Cells, Blood Substitutes and immobilization Biotechnology, an International Journal, 25: 1-24, 1997. Courtesy of Marcel Dekker Inc., NY	78

LIST OF TABLES

No.	Title	Page
1	Characteristics of Fluosol [®] (Green Cross Corporation, Japan) and Perftoran [®] (Perftoran Company, Russia)	51
2	Composition and characteristics of Oxygent [™] (Alliance Pharmaceutical Corporation, USA)	52
3	Side effects of haemoglobin solutions	58
4	Current Status of Development of Artificial Oxygen Carriers	62
5	Characteristics of Haemoglobin-Based Oxygen Carriers	64

ABBREVIATIONS

AIDS	: Acquired Immune Deficiency Virus
ARDS	: Acute Respiratory Distress Syndrome
CABG	: Coronary Artery Bypass Graft
CAT	: Catalase
CFR	: Code of Federal Regulations
DCLH	: Diaspirin cross-linked hemoglobin
DIC	: Dissiminated Intravascular Coagulopathy
DPG	: Diphosphoglycerate
FDA	: Food and Drug Administration
GVHD	: Graft-versus-host disease
Hb or Hgb	: Hemoglobin
HBOC	: Hemoglobin-based oxygen carrier
HIV	: Human Immune deficiency virus
HLA	: Human Leukocyte Antigen
HLK	: Hemolink
HNA	: Human Neutrophil Antigen
LAIR	: Leukocyte-associated immunoglobulin-like receptor
MP4	: Malemide-activated polyethylene glycol-modified haemoglobin
PFCs	: Perfluorocarbons
RBCs	: Red Blood Cells
rHb1.1	: Human recombinant hemoglobin
RSR13	: Allosteric modifier
SARS	: Severe Acute Respiratory Syndrome
SOD	: Super Oxide Dismutase
TRALI	: Transfusion Related Acute Lung Injury

INTRODUCTION

INTRODUCTION

The need for human blood for blood transfusion is steadily increasing due to an increase in ageing population, and decreased allogenic donations. However, donated human blood has many problems^[1].

The maintenance of intravascular volume is essential and resuscitation with isotonic crystalloid or volume expanders such as gelofusin or pentastarch is fundamental in the management of shock, with the addition of packed red cells when available, to restore oxygen carrying capacity and oxygen delivery to reinstate tissue perfusion^[2].

There are two main indications for the transfusion of red cells:

1. Severe haemorrhage.
2. Chronic symptomatic anaemia for which no specific therapy exist^[3].

Although of its great benefits, donated blood may exert an immunosuppressive effect on the recipient, making them more susceptible to infections, and may lead to various metabolic conditions, such as, Hyperkalemia, Hypocalcemia and Alkalosis^[4].

The development of artificial oxygen carriers began in 1933, and include:

1. Perfluorocarbons: they are synthetic oxygen carriers composed of eight to ten hydrocarbon molecules where the hydrogen atom has been replaced by fluorine, they are biologically and chemically inert. They possess high gas dissolving properties. They are not miscible with water and therefore have to be brought into an

emulsion prior to use. Perfluorocarbons have short intravascular half-life of 12-18 hours, but are only cleared from the body weeks later, preventing multiple doses in a short time span^[5].

2. Haemoglobin-based solution: they would seem to be a natural substitute for red cells that need some chemical modification to form a stable, functional tetramer of hemoglobin which would not dissociate into dimers upon infusion. They are derived from three principal sources: human, bovine and genetically engineered hemoglobin^[6].

The requisites for artificial oxygen carriers that develop should be not only effectiveness for tissue oxygenation, but also the following:

1. No blood type antigen and no infection.
2. Stability for long-term storage at room temperature.
3. Low toxicity and prompt metabolism, even after massive infusion.
4. Physicochemical properties that are adjustable to resemble those of human blood.
5. Reasonable production expense and cost performance^[7].